'Subgroup analysis' presentation slideshows

Antiplatelet therapy and Coronary Interventions

Antiplatelet therapy and Coronary Interventions. Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003. Objectives. Pharmacology of GP IIb/IIIa inhibitors and Monitoring of Platelet Inhibition Appropriate Use of GP IIb/IIIa inhibitors during PCI The Thienopyridines

819 views • 64 slides

Omid gharooei ahangar

Omid gharooei ahangar. definition. PCOS is the most common form of chronic anovulation associated with androgen excess; it occurs in perhaps 5% to 10 % of reproductive-age women .

1.1k views • 61 slides

697 views • 58 slides

Role of ARV as Prevention

Role of ARV as Prevention. Martin Fisher Brighton and Sussex University Hospitals, UK. New HIV diagnoses (Adjusted) among MSM, UK, 2001-2010. Global HIV Epidemic. The number of new infections exceeds the number of new cases starting ART 5 million untreated at <200; 10 million at <350.

643 views • 58 slides

Testing for mediating and moderating effects with SAS

Testing for mediating and moderating effects with SAS. Contingency / elaboration / 3rd variable models. One best management practice vs. contingency perspective Failure to find main effects -> use of moderators

643 views • 47 slides

Why and how to target treatment? Use of subgroup analysis and risk modelling

Why and how to target treatment? Use of subgroup analysis and risk modelling. Peter M Rothwell JLA/Lancet Conference June 2007. Treating individuals. Is this trial relevant to my patient? External validity Is the overall average treatment effect likely to be relevant to my patient?

412 views • 30 slides

CILON-T Late Breaking Trial : Randomized prospective trial of dual vs. triple antiplatelet therapy after DES implantatio

CILON-T Late Breaking Trial : Randomized prospective trial of dual vs. triple antiplatelet therapy after DES implantation . ACC & i2 summit, March 15th 2010, Atlanta, Georgia. Hyo-Soo Kim, MD, PhD Seoul National University Hospital Seoul, Korea . Nothing to disclose . CILON-T trial .

535 views • 29 slides

AASLD 2010 HCV Feedback

AASLD 2010 HCV Feedback. October 29 - November 2, 2010 Boston, Massachusetts Dr Allister J Grant Consultant Hepatologist Leicester Liver Unit. Boceprevir and Telaprevir. Boceprevir, a potent inhibitor of HCV NS3 protease Telaprevir, a potent inhibitor of HCV NS3/4A protease

388 views • 28 slides

EBM ?? ??? ??? ???

EBM ?? ??? ??? ???. ???? ?????? ?????? ?????? ??????. Free form question. The role of albumin use in resuscitation of trauma patients. Structured question. Critically ill. Population: major trauma patients with unstable hemodynamics in intensive care units.

439 views • 27 slides

Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF Trial

CLINICAL TRIAL UPDATE I. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF Trial.

448 views • 27 slides

Workshop on Patient Level Simulation Modelling

Workshop on Patient Level Simulation Modelling. Welcome and Introduction Sheffield Experiences of Patient Level Simulation Alan Brennan and Jim Chilcott, HEDS, ScHARR, CHEBS . Purpose of Today / Focus Fortnight.

398 views • 24 slides

Disclosure: Gianluca Masi

A randomized study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO).

449 views • 22 slides

Quality Improvement Strategies

Quality Improvement Strategies. Root Cause and Subgroup Analyses. Root Cause Analysis. A way of looking at unexpected events and undesirable outcomes to determine all of the underlying causes and recommend changes that are likely to improve them. 2. Root Cause Analysis.

719 views • 19 slides

Roxana Mehran, on behalf of the ACUITY investigators

Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa Inhibitor: Results from the Randomized ACUITY Trial. Roxana Mehran, on behalf of the ACUITY investigators. Disclosures. Medical

297 views • 16 slides

UOG Journal Club: October 2019

606 views • 15 slides

Nithima Sumpradit, PhD 1 Frank J. Ascione, PharmD. PhD 2 Richard P. Bagozzi, PhD 3

309 views • 13 slides

Re-ranking Subgroups for Fraud Detection

219 views • 12 slides

Biomarker & Subgroup Analysis & Identification Subteam of QSPI Multiplicity Working Group

Biomarker & Subgroup Analysis & Identification Subteam of QSPI Multiplicity Working Group. Goals and tasks. Ilya Lipkovich, Quintiles. General objectives. Formed under multiplicity team of QSPI http://biopharmnet.com/wiki/QSPI_Subgroup_Analysis_Working_Group

226 views • 8 slides

Hisao Ogawa et al. JAMA 2008;300:2134-2141

176 views • 7 slides

Capecitabine 2000mg d1-14 Q3wks x 6 cycles (n = 299)

Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907.

183 views • 6 slides